The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...

Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

To establish whether VTRs in ALT cells are contained within terminal repeats, we assessed the frequency of non-canonical telomeric repeats within the first 30 nucleotides from the 5’ of the Illumina ...

Search for other works by this author on: ...

Washington University in St. Louis, Saint Louis, MO.

Chemistry Department, School of Life Sciences, University of Sussex, Brighton BN1 9QJ, U.K. Bio-Techne (Tocris), The Watkins Building, Atlantic Road, Avonmouth ...